The goal of the COE program is to establish a global network of centers with expertise in distinct research areas to expand the utility of the DSP platform. Centers of Excellence will be the first to have access to DSP and an emerging menu of content. Each COE will establish a consortium of users and conduct technology workshops to increase awareness of DSP and generate impactful data demonstrating the utility of highly multiplexed spatial analysis. The Netherlands Cancer Institute will lead the European Center of Excellence with specific expertise in clinical applications and biomarker development on the DSP platform.
"We are excited to lead the DSP Center of Excellence to develop clinical research applications and identify novel biomarkers on this platform," said Dr. Christian Blank, Group Leader of Immunology at the Netherlands Cancer Institute. "Already DSP has provided us with independent validation of mechanisms of relapse following combination immunotherapy in melanoma, and we believe this partnership will lead to more discoveries in the field of oncology with the potential to impact the way we think of treatment."
"Establishing Centers of Excellence will enhance the awareness and establish the utility of the Digital Spatial Profiling platform for clinical research and biomarker development," said Chad Brown, senior vice president of sales & marketing at NanoString. "We look forward to working with Dr. Blank and the Netherlands Cancer Institute to demonstrate the unique capabilities of our DSP technology in advance of our full commercial launch expected in the first half of 2019."
Read more on the NanoString website